About Us

Our History Executive
Team Compliance

We are a focused organization

We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes. We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.

30 Years. Developing Innovative Therapies

Our history

EXPLORE OUR INTERACTIVE TIMELINE

Learn about the evolution of VIVUS and the expansion of our business globally. Swipe, click through or select a year to navigate our interactive timeline.

Timeline of Vivus history
PREVIOUS NEXT
1991. VIVUS is founded. 1994. VIVUS completes initial public offering. 1997. U.S. FDA approves MUSE® (alprostadil) reproductive health treatment in the U.S. 2005. VIVUS announces focus on developing obesity treatments. 2009. Two Phase 3 U.S. clinical trial results for QSYMIA® (phentermine and topiramate extended-release capsules) CIV announced. 2010. VIVUS announces sale of MUSE® (alprostadil) reproductive health treatment to Meda. 2012 U.S. FDA approves use of STENDRA® (avanafil) 2012 U.S. FDA approval and launch of QSYMIA® (phentermine and topiramate extended-release capsules) CIV treatment for adult patients in the U.S. 2013 EU EMA approval of SPEDRA® (avanafil) 2014 U.S. FDA approves a supplemental new drug application for the a rapid onset of action for STENDRA® (avanafil) 2016 VIVUS announces license agreement providing commercial rights to STENDRA® (avanafil) to Metuchen Pharmaceuticals 2018 VIVUS acquires all product rights for PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada 2019 South Korean MFDS approves QSYMIA® (phentermine and topiramate extended-release capsules) CIV for adult patients in South Korea 2020 VIVUS receives court approval for process to emerge from proceedings as a wholly-owned subsidiary of Icahn Enterprises L.P. 2020 Launch of QSYMIA® (phentermine and topiramate extended-release capsules) CIV for adult patients in South Korea 2020 U.S. FDA approves QSYMIA® (phentermine and topiramate extended-release capsules) CIV for pediatric patients aged 12-17 in the United States 2022 Market authorizations for QSIVA® (phentermine and topiramate modified-release) hard capsules granted in Sweden, Denmark, Finland, Iceland, Norway, and Poland 2022 VIVUS opens its European headquarters 2023 Initial launch of QSIVA® (phentermine and topiramate modified-release) hard capsules in Europe along with submission of additional individual authorization applications

BACK TO TOP

Helpful Links and Resources

LOCATIONS

ABOUT VIVUS

FOLLOW US